GEA 03t
Alternative Names: GEA-03tLatest Information Update: 12 Jul 2022
At a glance
- Originator GenEros BioPharma
- Class Anti-inflammatories
- Mechanism of Action TYK2 kinase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Systemic lupus erythematosus
Most Recent Events
- 20 Jun 2022 Preclinical trials in Systemic lupus erythematosus in China (unspecified route) (GenEros Biopharma pipeline, June 2022)